Atea Pharmaceuticals, Inc. (AVIR) Free cash flow 2019–2023
Atea Pharmaceuticals, Inc. (AVIR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$87.3MFY2023 · since FY2019: -$12.8M → -$87.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$87.3M | +27.8% |
| FY2022 | -$121.0M | -39.0% |
| FY2021 | -$87.0M | -129.3% |
| FY2020 | $296.7M | +2410.8% |
| FY2019 | -$12.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AVIR financial trends
AVIR RevenueAVIR Net incomeAVIR Net marginAVIR Gross profitAVIR Gross marginAVIR Operating incomeAVIR Operating marginAVIR Operating cash flowAVIR Capital expendituresAVIR Return on equityAVIR Stock buybacksAVIR Dividends paidAVIR Total assetsAVIR Total liabilitiesAVIR Shareholders’ equityAVIR overview →